



CANADIAN LISTING:
(PENDING)

I POT

1600-595 Burrard Street
Vancouver, BC V7X 1L3 Canada

ISRAEL'S FIRST PURE-PLAY CANNABIS FIRM

Focused on becoming a premier, low-cost cannabis producer. Isracann is fully funded for its 230,000 sq. ft. facility that is currently under development.

The company is targeting an undersupplied domestic market and anticipates near-term expansion to major European marketplaces.

SHARE CLASS	NO. OF SHARES	VALUE
CSE: AKE	38,315,000	\$19,541,000
Isracann Biosciences Inc.	70,000,000	\$35,700,000
Pre-Money	108,315,000	\$55,241,000
Financing (@\$0.51)	19,608,000	\$10,000,000
Post-Money	127,923,000	\$65,241,000
Cash Balance Post-Financing		\$15,000,000

Recently closed \$5.2MM First Tranche of Financing

LOCATION

Located in the cannabis research capital of the world, Isracann has relationships with Israeli research, scientific and medical community to identify opportunities and develop pipeline of drugs and devices.

Optimal Climatic Conditions to Grow Medical Cannabis



Low-cost Operations

Optimal climate and infrastructure allow for greenhouses and low-cost production of approx. \$0.40/gram

Leading Research Centre

Researchers in Israel have been studying cannabis for 50 years

Agricultural Innovation

Israel is world renowned as an agricultural innovation hub

Leading Partnerships

Partnered with leading research facilities with access to Hebrew University, Technion-Israel Institute of Technology to identify and develop a pipeline of strains, pharmaceuticals, and devices.



FACILITY

Licensed

Secured deals with three farms in Israel to lease their land for medicinal marijuana cultivation, all currently hold cultivation licenses

Significant Size


Fully funded capacity of 232,900 sq. ft. with the ability to produce 23,500 kg annually.

Expansion Opportunity

Scalable to over 580,000 sq. ft. producing 50,000kg annually

Engineering

Partnership with Yamko, a global construction agricultural projects worldwide in more than 70 countries.



NAME	HERMON 910	CAT. NO.	
FILE NAME	SADASH /ADRIIS	COORDINATOR	
DESIGN	Baris	DATE	05.07.17
APPROVE		REVISION	0
SCALE	Not to scale		

YAKO-YADRYZ
INDUSTRIES LTD. (P.2. GRP)

MARKET OPPORTUNITY

Cannabis


One of the fastest growing consumer segments ever, with an estimated global market size of \$146.6B by 2025

Domestic

10,000 patients in Israel currently on waitlist. Massively underserved domestic market presents significant and immediate opportunity

International

Israeli government legalized exports as of Jan 2019. European Union countries in close proximity, such as Germany, present a significant opportunity as they face undersupply



- Largely decriminalized
- Generic medical use
- Medical use by exception
- Illegal

THE TEAM

- Darryl Jones**, President & CEO
- Brett Allan**, Director
- Nitin Kaushal**, Strategic Advisor
- Mark Zegal**, Strategic Advisor
- Israel Moseson**, COO
- Mathew Christopherson**, Advisory Board Member
- Deepak Anand**, Advisory Board Member
- Vivian Bercovici**, Consultant

CORPORATE INFO

Isracann Biosciences Inc.
1600 - 595 Burrard Street
Vancouver, BC V7X 1L3 Canada
Darryl Jones, President
+1.604.788.9533
djones@isracann.com
www.isracann.com

AUDITOR

Davidson & Company LLP
1200 - 609 Granville Street,
Vancouver, BC V7Y 1G6 Canada

CORPORATE COUNSEL

Miller Thomson LLP
400 - 725 Granville Street
Vancouver, BC V7Y 1G5 Canada

Disclaimer

The information contained herein is provided by the management of Isracann Biosciences Inc. This document does not constitute the solicitation of the purchase or sale of securities. Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which are subject to risks and uncertainties.

isracann
BIOSCIENCES

CANADIAN LISTING:
(PENDING) **I POT**

